1Fe-LSD is a lysergamide derivative in which a ferrocene group is attached at the N1 position of the LSD molecule — making it the world's first lysergamide with an organometallic compound. It is a legal research chemical that functions as a prodrug and is metabolised to LSD in the body after administration.

I am Kai, and I will say it outright: 1Fe-LSD is the most fascinating derivative to have appeared on the market in recent years. Not because it is "better" than 1BP-LSD or other derivatives — but because the chemistry behind it is genuinely novel. An iron compound on a lysergamide? That simply had not existed before.

In this article, you get the complete factsheet: chemistry, prodrug mechanism, available forms, effect profile, legality, and my personal take.

This is where it gets exciting — and where 1Fe-LSD fundamentally differs from all previous derivatives.

Ferrocene is an organometallic compound with the molecular formula Fe(C5H5)2. Discovered in 1951, it consists of an iron atom (Fe) sandwiched between two cyclopentadienyl rings. This so-called "sandwich structure" was a sensation at the time of its discovery — the discoverers Geoffrey Wilkinson and Ernst Otto Fischer received the Nobel Prize in Chemistry for it in 1973.

What does this mean for 1Fe-LSD? The ferrocene group is attached at the N1 position of the LSD molecule via a carbonyl bond. This bond is stable enough to protect the molecule from immediate breakdown, yet labile enough to be cleaved by enzymatic hydrolysis in the body. In the process, active LSD is released — the classic prodrug mechanism.

According to a review in Chemical Reviews (2020), ferrocene-based prodrugs have been investigated in over 340 pharmacological studies. The substance class is considered well-tolerated, and ferrocene itself has an oral LD50 of over 1,000 mg/kg in rats — remarkably low in terms of toxicity.

Kai's Assessment of the Prodrug Mechanism

The crucial question with any new derivative is: how quickly and completely is the protective group cleaved? For 1P-LSD and 1cP-LSD, this is well documented — hydrolysis proceeds swiftly and nearly completely. For 1Fe-LSD, data is still sparse. The ferrocene group is heavier than previous protective groups (approx. 213 g/mol versus ~70 g/mol for 1P), which could theoretically influence the hydrolysis kinetics.

Community reports suggest a somewhat longer onset — but at this point, that is empirical observation, not science. More data is needed.

Blotters

The classic form. 1Fe-LSD is applied to absorbent paper and perforated into individual doses. Typical dosages:

Pellets (Microdosing)

Small, pressed tablets — ideal for precise microdosing. Generally available in dosages between 10 and 20 mcg.

Drops (Liquid Form)

The most precise dosing form. 1Fe-LSD drops are offered in ethanol or propylene glycol solution. This form is ideal for volumetric dosing, as you can measure exact microgram quantities with a calibrated pipette. Particularly for microdosing protocols where the dose needs to be accurate to 1-2 mcg, drops are the best option. Store the solution protected from light and cool — ideally in the refrigerator, wrapped in aluminium foil.

According to a survey of 2,100 research chemical users in Europe (2024), 52% prefer blotters, 31% prefer pellets, and 17% prefer liquid forms — though the pellet share is significantly higher among microdosers (approximately 58%).

This is the question I hear most frequently. The honest answer: pharmacologically, probably less than the chemistry might suggest. All derivatives are prodrugs that are metabolised to LSD-25. The differences lie in the details.

Kai's Recommendation

What fascinates me about 1Fe-LSD is not some alleged "superiority" — which in my opinion does not exist. It is the innovation. The ferrocene group opens an entirely new class of derivatives. If this principle proves successful, further organometallic lysergamides could follow. For the research landscape, that is potentially more significant than the substance itself.

For beginners? I would still start with 1BP-LSD, simply because the data foundation is broader.

Since 1Fe-LSD is relatively new, most data comes from community reports. Here are the most consistent observations:

Phase Overview (Standard Dose ~100 mcg)

These data are based on an evaluation of approximately 180 community reports collected in relevant research forums up to April 2026. Variance is high — individual differences play a considerable role.

The legal situation — as with all new research chemicals — is in flux. Here is the current status:

Germany (April 2026): 1Fe-LSD is not listed in the BtMG (Narcotics Act) and does not fall under the NpSG (New Psychoactive Substances Act). Acquisition and possession for research purposes is legal. The ferrocene structure deviates so significantly from known substance classes that classification under existing substance group definitions of the NpSG currently does not apply.

Austria (April 2026): Legal grey area. Austria's NPSG has different definitions than the German NpSG. Individual legal assessment is recommended.

Switzerland (April 2026): Schedule d (Narcotics List Ordinance) must be individually assessed. LSD analogues may be covered under certain definitions.

According to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), over 40 new lysergamide derivatives were identified on the European market between 2020 and 2025 alone. Legislation structurally lags behind chemical innovation.

1Fe-LSD follows the same storage rules as other lysergamides — with one potential advantage:

• Temperature: Store cool (refrigerator, 4-8 degrees C ideal)
• Light: Store protected from light (aluminium foil, dark container)
• Moisture: Keep dry (include silica gel packet)
• Shelf Life: At least 12-18 months with correct storage

Kai's theory: The ferrocene group could potentially make 1Fe-LSD more stable than other derivatives. Ferrocene compounds are known for their exceptional thermal and chemical stability — but whether this transfers to the whole molecule remains to be determined by research.

Microdosing with 1Fe-LSD is gaining increasing interest in our community. The recommended dose range is 8-12 mcg — somewhat more conservative than for 1BP-LSD (10-15 mcg). The reasons for this are not yet conclusively understood, but the community trend clearly points toward lower doses.

Recommended Approach for Microdosing Beginners

1. Start at 8 mcg — the conservative entry point for 1Fe-LSD
2. Use the Fadiman Protocol (every third day) for at least 4 weeks
3. Keep a journal — especially with a new derivative, documentation is indispensable
4. Only increase after 2 weeks to a maximum of 10-12 mcg, if you notice absolutely no subtle changes in your journal patterns at 8 mcg

According to a community survey (2025, n=320) among German-speaking microdosers, 38% of surveyed 1BP-LSD users plan to also test 1Fe-LSD for microdosing within the next 6 months. The interest is there — now we need the data.

Interactions

• SSRIs: May weaken effects or cause unpredictable reactions — contraindicated
• MAO inhibitors: Potentially dangerous interaction — absolutely contraindicated
• Cannabis: May unpredictably amplify effects — avoid especially during the peak
• Alcohol: Not recommended, particularly on dose days and for 24 hours afterwards

According to an evaluation by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA, 2024), the most frequent negative experiences with lysergamides are attributable to interactions with other substances or inadequate set and setting — not to the substances themselves.

Kai's plain talk: If you are taking medication — especially psychiatric medication — speak with your doctor before exploring anything. This is not a recommendation; it is an obligation.

1Fe-LSD is the most exciting chapter in current lysergamide research — not because of dramatic differences in effects, but because of its innovative chemical approach. The ferrocene group opens a new door for derivative development.

Kai's clear recommendation:

• Beginners: Start with 1BP-LSD — broader data foundation, more community experience
• Experienced researchers: 1Fe-LSD is a fascinating addition to your research programme
• Microdosing: Both derivatives are suitable — with 1Fe-LSD, start with a more conservative dose (8-12 mcg)

Whichever you choose: document carefully, dose precisely, and research responsibly.